TABLE 3.

Adjusted OR for NOAC use according to each renal endpoint in patients with and without diabetes

	With diabetes		Without diabetes
	OR (95% CI)	P value	OR (95% CI)	P value
Median annual decline of eGFR
Dabigatran	0.621 (0.345‐1.117)	0.112	0.734 (0.528‐1.020)	0.065
Rivaroxaban	0.777 (0.455‐1.329)	0.357	0.741 (0.534‐1.029)	0.073
Apixaban	0.591 (0.326‐1.073)	0.084	0.822 (0.606‐1.113)	0.205
Incident eGFR <50 mL/min
Dabigatran	0.406 (0.146‐1.125)	0.083	0.527 (0.292‐0.952)	0.034
Rivaroxaban	0.677 (0.285‐1.610)	0.378	0.599 (0.334‐1.073	0.085
Apixaban	0.261 (0.081‐0.839)	0.024	0.497 (0.288‐0.857)	0.012
eGFR class worsening
Dabigatran	1.127 (0.578‐2.198)	0.725	0.611 (0.415‐0.898)	0.012
Rivaroxaban	0.789 (0.412‐1.511)	0.475	0.539 (0.363‐0.800)	0.002
Apixaban	0.690 (0.327‐1.453)	0.329	0.567 (0.396‐0.813)	0.002

Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; OR, odds ratio.